John Newman
Stock Analyst at Canaccord Genuity
(2.00)
# 2,891
Out of 4,944 analysts
79
Total ratings
41.18%
Success rate
-8.63%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 | $561.55 | +51.37% | 17 | Jul 23, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.04 | +1,246.15% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $112.78 | +52.01% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $12.13 | +40.15% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.29 | +520.16% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $6.40 | +290.63% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $200 | $15.97 | +1,152.35% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $11.11 | +89.02% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $70.90 | +62.20% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.69 | +1,066.18% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $67.22 | -0.33% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $11.81 | +264.10% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.02 | +390.20% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $36.61 | +20.19% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $16.07 | +136.47% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.37 | +402.79% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $12.01 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Jul 23, 2025
Maintains: Buy
Price Target: $850
Current: $561.55
Upside: +51.37%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.04
Upside: +1,246.15%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $112.78
Upside: +52.01%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $12.13
Upside: +40.15%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.29
Upside: +520.16%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $6.40
Upside: +290.63%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $200
Current: $15.97
Upside: +1,152.35%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $11.11
Upside: +89.02%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $70.90
Upside: +62.20%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.69
Upside: +1,066.18%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $67.22
Upside: -0.33%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $11.81
Upside: +264.10%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.02
Upside: +390.20%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $36.61
Upside: +20.19%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $16.07
Upside: +136.47%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.37
Upside: +402.79%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $12.01
Upside: -